<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Biovie Inc — News on 6ix</title>
<link>https://6ix.com/company/biovie-inc</link>
<description>Latest news and press releases for Biovie Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/biovie-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354d8878dffbe2df0e5fc9.webp</url>
<title>Biovie Inc</title>
<link>https://6ix.com/company/biovie-inc</link>
</image>
<item>
<title>BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026</title>
<link>https://6ix.com/company/biovie-inc/news/biovie-to-host-virtual-kol-event-to-discuss-the-phase-2-study-of-bezisterim-for-the-treatment-of-parkinsons-disease-ahead-of-topline-data-in-2q26-on-may-7-2026</link>
<guid isPermaLink="true">https://6ix.com/company/biovie-inc/news/biovie-to-host-virtual-kol-event-to-discuss-the-phase-2-study-of-bezisterim-for-the-treatment-of-parkinsons-disease-ahead-of-topline-data-in-2q26-on-may-7-2026</guid>
<pubDate>Mon, 27 Apr 2026 12:00:00 GMT</pubDate>
<description>CARSON CITY, Nev., April 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that it will host a virtual key opinion leader (KOL) event on Thursday, May 7, 2026 at 2:00 PM ET featuring Suzanne de la Monte, MD, MPH (Brown University Warren Alpert Medical School, Providence VA Medical Center), who will join company management to discuss how</description>
</item>
<item>
<title>BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting</title>
<link>https://6ix.com/company/biovie-inc/news/biovie-announces-abstract-accepted-for-presentation-at-the-2026-american-academy-of-neurology-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/biovie-inc/news/biovie-announces-abstract-accepted-for-presentation-at-the-2026-american-academy-of-neurology-annual-meeting</guid>
<pubDate>Tue, 14 Apr 2026 04:00:00 GMT</pubDate>
<description>CARSON CITY, Nev., April 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative</description>
</item>
<item>
<title>BioVie Announces Abstract Accepted for Presentation at AD/PD 2026</title>
<link>https://6ix.com/company/biovie-inc/news/biovie-announces-abstract-accepted-for-presentation-at-adpd-2026-6</link>
<guid isPermaLink="true">https://6ix.com/company/biovie-inc/news/biovie-announces-abstract-accepted-for-presentation-at-adpd-2026-6</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>CARSON CITY, Nev., March 12, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative</description>
</item>
<item>
<title>Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on March 4</title>
<link>https://6ix.com/company/biovie-inc/news/join-biovies-exclusive-live-investor-webinar-and-qanda-session-on-march-4</link>
<guid isPermaLink="true">https://6ix.com/company/biovie-inc/news/join-biovies-exclusive-live-investor-webinar-and-qanda-session-on-march-4</guid>
<pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
<description>CARSON CITY, Nev., Feb. 23, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative</description>
</item>
<item>
<title>BioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual Meeting</title>
<link>https://6ix.com/company/biovie-inc/news/biovie-announces-abstracts-accepted-presentation-130000258</link>
<guid isPermaLink="true">https://6ix.com/company/biovie-inc/news/biovie-announces-abstracts-accepted-presentation-130000258</guid>
<pubDate>Thu, 12 Feb 2026 13:00:00 GMT</pubDate>
<description>CARSON CITY, Nev., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the acceptance of two abstracts from studies on its lead candidate bezisterim (NE3107), in the treatment of Alzheimer’s Disease and Long COVID at the 2026 American College of Psychiatrists (ACP) annual meeting, to be held February 18-22, in Bonita Springs, FL. The</description>
</item>
<item>
<title>BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson’s Disease</title>
<link>https://6ix.com/company/biovie-inc/news/biovie-completes-enrollment-phase-2-130000612</link>
<guid isPermaLink="true">https://6ix.com/company/biovie-inc/news/biovie-completes-enrollment-phase-2-130000612</guid>
<pubDate>Thu, 08 Jan 2026 13:00:00 GMT</pubDate>
<description>- Patient-centric trial aiming to evaluate whether bezisterim can help delay disease progression reaches enrollment milestone - - Topline Results from the SUNRISE-PD Trial Expected in 1H 2026 - CARSON CITY, Nev., Jan. 08, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that it has completed enrollment of 60 patients in its Phase 2 SUNRISE</description>
</item>
<item>
<title>Bench International Announces Appointment of Jim Lang to the Board of Directors of Halozyme Therapeutics</title>
<link>https://6ix.com/company/biovie-inc/news/bench-international-announces-appointment-of-jim-lang-to-the-board-of-directors-of-halozyme-therapeutics</link>
<guid isPermaLink="true">https://6ix.com/company/biovie-inc/news/bench-international-announces-appointment-of-jim-lang-to-the-board-of-directors-of-halozyme-therapeutics</guid>
<pubDate>Wed, 17 Dec 2025 13:30:00 GMT</pubDate>
<description>Bench International today announced the appointment of Jim Lang to the Board of Directors of Halozyme Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on advancing innovative drug delivery technologies that improve how medicines are delivered to patients worldwide.</description>
</item>
<item>
<title>Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on December 9</title>
<link>https://6ix.com/company/biovie-inc/news/join-biovie-exclusive-live-investor-130000489</link>
<guid isPermaLink="true">https://6ix.com/company/biovie-inc/news/join-biovie-exclusive-live-investor-130000489</guid>
<pubDate>Wed, 19 Nov 2025 13:00:00 GMT</pubDate>
<description>CARSON CITY, Nev., Nov. 19, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, is pleased to invite investors to a webinar on December 9, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Cuong Do, President and CEO of BioVie, who will discuss bezisterim (NE3107), BioVie’s first-in-class, orally available small molecule t</description>
</item>
<item>
<title>BioVie to Host Live Investor Webinar and Q&A on Oct. 8</title>
<link>https://6ix.com/company/biovie-inc/news/biovie-host-live-investor-webinar-120000019</link>
<guid isPermaLink="true">https://6ix.com/company/biovie-inc/news/biovie-host-live-investor-webinar-120000019</guid>
<pubDate>Fri, 26 Sep 2025 12:00:00 GMT</pubDate>
<description>CARSON CITY, Nev., Sept. 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, will host an investor webinar at 4:15 p.m. ET on Wednesday, Oct. 8, 2025. The exclusive event, hosted by RedChip Companies, will feature Cuong Do, president and CEO of BioVie, who will discuss bezisterim (NE3107), the company’s first-in-class, orally available small molecule tha</description>
</item>
<item>
<title>BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes</title>
<link>https://6ix.com/company/biovie-inc/news/biovie-highlighted-address-lc-phase-200500689</link>
<guid isPermaLink="true">https://6ix.com/company/biovie-inc/news/biovie-highlighted-address-lc-phase-200500689</guid>
<pubDate>Wed, 13 Aug 2025 20:05:00 GMT</pubDate>
<description>ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue and cognitive impairment at sites across the U.S.CARSON CITY, Nev., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that a poster highlighting the design and enrichment strategy of its ongoing Phase 2 ADDRESS-LC trial will be presented at the Keystone Symp</description>
</item>
<item>
<title>BioVie Inc. Announces Closing of $12 Million Public Offering</title>
<link>https://6ix.com/company/biovie-inc/news/biovie-inc-announces-closing-12-200500001</link>
<guid isPermaLink="true">https://6ix.com/company/biovie-inc/news/biovie-inc-announces-closing-12-200500001</guid>
<pubDate>Mon, 11 Aug 2025 20:05:00 GMT</pubDate>
<description>CARSON CITY, Nev., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of its previously announced underwritten public offering of 6,000,000 units, with each unit consisting of one share of common stock and one warrant (the “Warrants”) (or pre-fund</description>
</item>
<item>
<title>BioVie Inc. Announces Pricing of $12 Million Public Offering</title>
<link>https://6ix.com/company/biovie-inc/news/biovie-inc-announces-pricing-12-004300122</link>
<guid isPermaLink="true">https://6ix.com/company/biovie-inc/news/biovie-inc-announces-pricing-12-004300122</guid>
<pubDate>Fri, 08 Aug 2025 00:43:00 GMT</pubDate>
<description>CARSON CITY, Nev., Aug. 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of its underwritten public offering of 6,000,000 units, with each unit consisting of one share of common stock and one warrant (the “Warrants”) (or pre-funded units in lieu ther</description>
</item>
<item>
<title>BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology</title>
<link>https://6ix.com/company/biovie-inc/news/biovie-presented-data-highlighting-patients-120000548</link>
<guid isPermaLink="true">https://6ix.com/company/biovie-inc/news/biovie-presented-data-highlighting-patients-120000548</guid>
<pubDate>Thu, 24 Jul 2025 12:00:00 GMT</pubDate>
<description>Bezisterim treatment appears to be associated with changes in DNA methylation of over 100 genes related to aging and diseases of agingCARSON CITY, Nev., July 24, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, presented “Bezisterim Decreases Biological Age Acceleration in Alzheimer’s Disease” at the 2nd World</description>
</item>
<item>
<title>BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors</title>
<link>https://6ix.com/company/biovie-inc/news/biovie-appoints-industry-veterans-amy-120000263</link>
<guid isPermaLink="true">https://6ix.com/company/biovie-inc/news/biovie-appoints-industry-veterans-amy-120000263</guid>
<pubDate>Tue, 22 Jul 2025 12:00:00 GMT</pubDate>
<description>Seasoned leaders bring deep expertise in neuroscience drug development, strategic growth, and corporate finance to support BioVie’s missionCARSON CITY, Nev., July 22, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the appointment of Amy S. Chappell, MD, FAAN, and Kameel D. Farag to its Board o</description>
</item>
<item>
<title>BioVie Announces Data Highlighting Bezisterim’s Potential to Slow or Reverse Biological Aging and Neurodegeneration Featured as a Keynote Talk at the 7th World Aging and Rejuvenation Conference</title>
<link>https://6ix.com/company/biovie-inc/news/biovie-announces-data-highlighting-bezisterim-120000482</link>
<guid isPermaLink="true">https://6ix.com/company/biovie-inc/news/biovie-announces-data-highlighting-bezisterim-120000482</guid>
<pubDate>Wed, 09 Jul 2025 12:00:00 GMT</pubDate>
<description>CARSON CITY, Nev., July 09, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, presented “Bezisterim Epigenetic Effects on Aging and Neurodegeneration” at the 7th World Aging and Rejuvenation Conference (ARC-2025) taking place in Vienna, Austria, July 9th –10th, 2025. Unlike historical approach to Alzheimer’s Dis</description>
</item>
<item>
<title>BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)</title>
<link>https://6ix.com/company/biovie-inc/news/biovie-highlights-patient-centric-design-120000967</link>
<guid isPermaLink="true">https://6ix.com/company/biovie-inc/news/biovie-highlights-patient-centric-design-120000967</guid>
<pubDate>Thu, 26 Jun 2025 12:00:00 GMT</pubDate>
<description>Hybrid, decentralized trial of bezisterim in early Parkinson’s Disease prioritizes patient access and participationCARSON CITY, Nev., June 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster highlighting the patient-centric design and accessibility of its ongoing SUNRISE-PD Phase</description>
</item>
<item>
<title>BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress</title>
<link>https://6ix.com/company/biovie-inc/news/biovie-present-overview-phase-2-200500897</link>
<guid isPermaLink="true">https://6ix.com/company/biovie-inc/news/biovie-present-overview-phase-2-200500897</guid>
<pubDate>Tue, 24 Jun 2025 20:05:00 GMT</pubDate>
<description>CARSON CITY, Nev., June 24, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster highlighting the decentralized design and patient experience of its Phase 2 SUNRISE-PD clinical trial evaluating bezisterim (NE3107) in early Parkinson’s disease will be presented in poster session at the</description>
</item>
<item>
<title>BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID</title>
<link>https://6ix.com/company/biovie-inc/news/biovie-enrolls-first-patient-address-120000130</link>
<guid isPermaLink="true">https://6ix.com/company/biovie-inc/news/biovie-enrolls-first-patient-address-120000130</guid>
<pubDate>Thu, 15 May 2025 12:00:00 GMT</pubDate>
<description>Despite growing recognition of long COVID as a serious condition, diagnosed patients have no approved treatment options, with many suffering from debilitating fatigue and brain fog Evidence suggests sustained inflammation plays a central role in the pathogenesis of long COVID, particularly in the associated cognitive dysfunction and other neurological symptoms1 Bezisterim targets key underlying mechanisms of neuroinflammation, and has demonstrated the potential to reduce chronic symptoms in Alzh</description>
</item>
<item>
<title>BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025</title>
<link>https://6ix.com/company/biovie-inc/news/biovie-host-virtual-kol-event-113000095</link>
<guid isPermaLink="true">https://6ix.com/company/biovie-inc/news/biovie-host-virtual-kol-event-113000095</guid>
<pubDate>Wed, 14 May 2025 11:30:00 GMT</pubDate>
<description>CARSON CITY, Nev., May 14, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that it will host a virtual key opinion leader (KOL) event featuring Suzanne de la Monte, MD, MPH (Brown University Warren Alpert Medical School, Providence VA Medical Center) and Mark Stacy, MD (Medical University of S</description>
</item>
<item>
<title>BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson’s Disease and Related Disorders (IAPRD 2025)</title>
<link>https://6ix.com/company/biovie-inc/news/biovie-present-rationale-design-phase-120000342</link>
<guid isPermaLink="true">https://6ix.com/company/biovie-inc/news/biovie-present-rationale-design-phase-120000342</guid>
<pubDate>Wed, 07 May 2025 12:00:00 GMT</pubDate>
<description>CARSON CITY, Nev., May 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that a poster on the rationale and design of its Phase 2 SUNRISE-PD clinical trial evaluating bezisterim (NE3107) in early Parkinson’s disease will be presented in a Guided Poster Tour session at the 30th World Congress</description>
</item>
</channel>
</rss>